Table 1

Characteristics of patients undergoing allogeneic HCT

Year of allogeneic HCT
1968-1986
1987-1990
1991-1996
1968-1996
Patients%Patients%Patients%Patients%
Total cohort 8719 100 8946 100 9236 100 26 901 100 
    CIBMTR 6721 77.1 7777 86.9 7645 82.8 22 143 82.3 
    FHCRC 1998 22.9 1169 13.1 1591 17.2 4758 17.7 
Sex         
    Male 5086 58.3 5296 59.2 5496 59.5 15 878 59.0 
    Female 3633 41.7 3650 40.8 3740 40.5 11 023 41.0 
Age at transplantation, y         
    Younger than 10 1403 16.1 1262 14.1 1243 13.5 3908 14.5 
    10-19 2336 26.8 1628 18.2 1461 15.8 5425 20.2 
    20-29 2400 27.5 2137 23.9 1748 18.9 6285 23.4 
    30-39 1853 21.3 2218 24.8 2222 24.1 6293 23.4 
    40-49 656 7.5 1472 16.5 1917 20.8 4045 15.0 
    50 y or older 71 0.8 229 2.6 645 7.0 945 3.5 
Median age (range) at transplantation, y 22.5 (0.2-67) NA 27.5 (0.1-62) NA 30.8 (0.2-68) NA 26.6 (0.1-68) NA 
Geographic region of transplant team         
    United States 3979 45.6 3418 38.2 4077 44.1 11 474 42.7 
    Canada 130 1.5 369 4.1 529 5.7 1028 3.8 
    Europe 3870 44.4 3845 43.0 3070 33.2 10 785 40.1 
    Other 740 8.5 1314 14.7 1560 16.9 3614 13.4 
Primary disease*         
    Acute lymphocytic leukemia 2226 25.5 1861 20.8 1704 18.5 5791 21.5 
    Acute nonlymphocytic leukemia 2615 30.0 2387 26.7 2366 25.6 7368 27.4 
    Chronic myelogenous leukemia 1860 21.3 2716 30.4 2882 31.2 7458 27.7 
    Severe aplastic anemia 1398 16.0 734 8.2 656 7.1 2788 10.4 
    Other 620 7.1 1248 14.0 1628 17.6 3496 13.0 
Donor recipient relationship and histocompatibility         
    HLA-identical sibling 7495 86.0 7060 78.9 6318 68.4 20 873 77.6 
    1 HLA antigen–mismatched related donor 615 7.1 700 7.8 444 4.8 1759 6.5 
    2+ HLA antigen–mismatched related donor 465 5.3 330 3.7 274 3.0 1069 4.0 
    Unrelated donor 83 1.0 819 9.2 2103 22.8 3005 11.2 
    Other, uncertain 61 0.7 37 0.4 97 1.1 195 0.7 
Transplantation conditioning regimen         
    TBI + Cy ± other drugs 6245 71.6 4876 54.5 4578 49.6 15 699 58.4 
    TBI + other drugs (no Cy) 738 8.5 771 8.6 683 7.4 2192 8.2 
    LFI ± Cy ± other drugs 339 3.9 319 3.6 145 1.6 803 3.0 
    Busulfan + Cy ± other drugs 440 5.1 2482 27.7 3355 36.3 6277 23.3 
    Cy ± other drugs 903 10.4 422 4.7 372 4.0 1697 6.3 
    Other 54 0.6 76 0.9 103 1.1 233 0.9 
T-cell depletion of marrow         
    No T-cell depletion 7425 85.2 7741 86.5 8189 88.7 23 355 86.8 
    Anti-T or anti-T + NK MoAb 684 7.8 568 6.4 532 5.8 1784 6.6 
    Sheep red blood cell (SRBC) rosetting 73 0.8 91 1.0 61 0.7 225 0.8 
    Lectins (including SRBC/MoAb) 62 0.7 74 0.8 87 0.9 223 0.8 
    Alemtuzumab (CAMPATH) MoAb 319 3.7 286 3.2 79 0.9 684 2.5 
    Elutriation/density gradient centrifugation 100 1.2 152 1.7 260 2.8 512 1.9 
    Unclassified/other 56 0.6 34 0.4 28 0.3 118 0.4 
Acute GVHD†         
    None, grade I 5238 60.1 5691 63.6 5397 58.4 16 326 60.7 
    Grades II-IV 3481 39.9 3255 36.4 3839 41.6 10 575 39.3 
Chronic GVHD†         
    None, mild 7251 83.2 7327 81.9 7552 81.8 22 130 82.3 
    Moderate, severe 1468 16.8 1619 18.1 1684 18.2 4771 17.7 
ATG         
    None 7755 88.9 8384 93.7 8493 92.0 24 632 91.6 
    GVHD prophylaxis only 307 3.5 150 1.7 221 2.4 678 2.5 
    Acute GVHD treatment only 612 7.0 382 4.3 488 5.3 1482 5.5 
    Both prophylaxis and acute GVHD treatment 45 0.5 30 0.3 34 0.4 109 0.4 
Second allogeneic HCT†         
    No 8123 93.2 8464 94.6 8843 95.7 25 430 94.5 
    Yes 596 6.8 482 5.4 393 4.3 1471 5.5 
Year of allogeneic HCT
1968-1986
1987-1990
1991-1996
1968-1996
Patients%Patients%Patients%Patients%
Total cohort 8719 100 8946 100 9236 100 26 901 100 
    CIBMTR 6721 77.1 7777 86.9 7645 82.8 22 143 82.3 
    FHCRC 1998 22.9 1169 13.1 1591 17.2 4758 17.7 
Sex         
    Male 5086 58.3 5296 59.2 5496 59.5 15 878 59.0 
    Female 3633 41.7 3650 40.8 3740 40.5 11 023 41.0 
Age at transplantation, y         
    Younger than 10 1403 16.1 1262 14.1 1243 13.5 3908 14.5 
    10-19 2336 26.8 1628 18.2 1461 15.8 5425 20.2 
    20-29 2400 27.5 2137 23.9 1748 18.9 6285 23.4 
    30-39 1853 21.3 2218 24.8 2222 24.1 6293 23.4 
    40-49 656 7.5 1472 16.5 1917 20.8 4045 15.0 
    50 y or older 71 0.8 229 2.6 645 7.0 945 3.5 
Median age (range) at transplantation, y 22.5 (0.2-67) NA 27.5 (0.1-62) NA 30.8 (0.2-68) NA 26.6 (0.1-68) NA 
Geographic region of transplant team         
    United States 3979 45.6 3418 38.2 4077 44.1 11 474 42.7 
    Canada 130 1.5 369 4.1 529 5.7 1028 3.8 
    Europe 3870 44.4 3845 43.0 3070 33.2 10 785 40.1 
    Other 740 8.5 1314 14.7 1560 16.9 3614 13.4 
Primary disease*         
    Acute lymphocytic leukemia 2226 25.5 1861 20.8 1704 18.5 5791 21.5 
    Acute nonlymphocytic leukemia 2615 30.0 2387 26.7 2366 25.6 7368 27.4 
    Chronic myelogenous leukemia 1860 21.3 2716 30.4 2882 31.2 7458 27.7 
    Severe aplastic anemia 1398 16.0 734 8.2 656 7.1 2788 10.4 
    Other 620 7.1 1248 14.0 1628 17.6 3496 13.0 
Donor recipient relationship and histocompatibility         
    HLA-identical sibling 7495 86.0 7060 78.9 6318 68.4 20 873 77.6 
    1 HLA antigen–mismatched related donor 615 7.1 700 7.8 444 4.8 1759 6.5 
    2+ HLA antigen–mismatched related donor 465 5.3 330 3.7 274 3.0 1069 4.0 
    Unrelated donor 83 1.0 819 9.2 2103 22.8 3005 11.2 
    Other, uncertain 61 0.7 37 0.4 97 1.1 195 0.7 
Transplantation conditioning regimen         
    TBI + Cy ± other drugs 6245 71.6 4876 54.5 4578 49.6 15 699 58.4 
    TBI + other drugs (no Cy) 738 8.5 771 8.6 683 7.4 2192 8.2 
    LFI ± Cy ± other drugs 339 3.9 319 3.6 145 1.6 803 3.0 
    Busulfan + Cy ± other drugs 440 5.1 2482 27.7 3355 36.3 6277 23.3 
    Cy ± other drugs 903 10.4 422 4.7 372 4.0 1697 6.3 
    Other 54 0.6 76 0.9 103 1.1 233 0.9 
T-cell depletion of marrow         
    No T-cell depletion 7425 85.2 7741 86.5 8189 88.7 23 355 86.8 
    Anti-T or anti-T + NK MoAb 684 7.8 568 6.4 532 5.8 1784 6.6 
    Sheep red blood cell (SRBC) rosetting 73 0.8 91 1.0 61 0.7 225 0.8 
    Lectins (including SRBC/MoAb) 62 0.7 74 0.8 87 0.9 223 0.8 
    Alemtuzumab (CAMPATH) MoAb 319 3.7 286 3.2 79 0.9 684 2.5 
    Elutriation/density gradient centrifugation 100 1.2 152 1.7 260 2.8 512 1.9 
    Unclassified/other 56 0.6 34 0.4 28 0.3 118 0.4 
Acute GVHD†         
    None, grade I 5238 60.1 5691 63.6 5397 58.4 16 326 60.7 
    Grades II-IV 3481 39.9 3255 36.4 3839 41.6 10 575 39.3 
Chronic GVHD†         
    None, mild 7251 83.2 7327 81.9 7552 81.8 22 130 82.3 
    Moderate, severe 1468 16.8 1619 18.1 1684 18.2 4771 17.7 
ATG         
    None 7755 88.9 8384 93.7 8493 92.0 24 632 91.6 
    GVHD prophylaxis only 307 3.5 150 1.7 221 2.4 678 2.5 
    Acute GVHD treatment only 612 7.0 382 4.3 488 5.3 1482 5.5 
    Both prophylaxis and acute GVHD treatment 45 0.5 30 0.3 34 0.4 109 0.4 
Second allogeneic HCT†         
    No 8123 93.2 8464 94.6 8843 95.7 25 430 94.5 
    Yes 596 6.8 482 5.4 393 4.3 1471 5.5 

The distribution under each subheading (in bold) is based on all subjects regardless of their status with respect to other variables in the table. Thus, the numbers under each subheading add to the totals at the top of the columns and the percentages add to 100%. Percentages do not always add to exactly 100% because of rounding.

CIBMTR indicates Center for International Blood and Marrow Research; FHCRC, Fred Hutchinson Cancer Research Center; TBI, total body irradiation; Cy, cyclophosphamide; LFI, limited field irradiation; GVHD, graft-versus-host disease; NK, natural killer; MoAb, monoclonal antibody; and ATG, antithymocyte globulin.

*

Primary diseases excluded from the analysis were non-Hodgkin lymphomas (n = 1092), Hodgkin lymphoma (n = 228), Fanconi anemia (n = 328), and immune-deficiency diseases (n = 532). Other primary diseases included other malignancies, myelodysplastic syndromes or myeloproliferative disorders, and other smaller groups of primarily nonmalignant diseases, including inherited disorders of metabolism, and hemoglobinopathies.

†

Number of patients with acute GVHD, chronic GVHD, or second transplantation that occurred before study exit date (date of last follow-up or date of PTLD diagnosis). Second allogeneic transplantation among patients with a first allogeneic transplantation.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal